Latest Content

Nivolumab displayed significant RFS benefit compared with ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

Gabriel Schwartz, MSN, NP, explains how mechanisms of action determine the safety of systemic treatments in metastatic colorectal cancer post chemotherapy.

Integrating PRO tools in survivorship care may help oncology nurses address ongoing emotional and physical needs of ovarian cancer survivors.

Here are 5 presentations that oncology APPs should know about, from patient management to practice management.

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings.

The FDA has approved ziftomenib for relapsed or refractory acute myeloid leukemia harboring NPM1 mutations with no alternative treatment options.

Kristi Orbaugh, MSN, RNP, AOCN, AOCNP, shared the key toxicities of each CDK4/6 inhibitor and how to monitor for them.

Care at every step is the ethical duty of nurses, says Katherine Brown-Saltzman, MA, RN, in this episode of Onc Nurse On Call.

After undergoing EBRT and brachytherapy at 14, an AYA cancer survivor discusses her experience with a rare vaginal cancer and Turner syndrome.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, explains that later cytopenias should be monitored in patients undergoing CAR T-cell therapy.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

The FDA has approved subcutaneous daratumumab and hyaluronidase-fihj for use in patients with high-risk smoldering multiple myeloma.

An oncology APP-led quality assurance committee identified key safety events across disciplines and specialties.